Intestinal Research

Original Articles

Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study: Kijae Jo, Kwang Woo Kim, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim, Seong-Joon Koh; Received March 20, 2024 Accepted April 15, 2024 Published online May 22, 2024; DOI: https://doi.org/10.5217/ir.2024.00044 [Epub ahead of print]

Abstract PDF PubReader ePub: Background/Aims
The prevalence and incidence of ulcerative colitis (UC) in Korea is increasing. Each patient has a different disease course and treatment response. Recently, with the development of biologic agents, histological remission has become a treatment goal. In this study, we aimed to identify the predictors of histological remission after first-line biologic agent treatment in patients with biologic agent-naïve UC.
Methods
We retrospectively analyzed the medical records of 92 patients who had been diagnosed with UC and treated with first-line biologic agent treatment at our center, between 2015 and 2022. The clinical characteristics, laboratory test results, and endoscopic and biopsy findings were analyzed. Histological remission was defined as the absence of cryptitis, crypt abscesses, and inflammatory cells on histology. Univariate and multivariate logistic regression analyses were performed to identify the predictors of histological remission after first-line treatment.
Results
Of the total 92 patients, 25 (27.2%) achieved histological remission. Each cohort had a varied body mass index (BMI) distribution, with a statistically significant overweight ratio, as defined by the Asian-Pacific BMI category of 23–25 kg/m², of 48.0% in the histological remission cohort (P= 0.026). A causal correlation between the overweight category and histological remission was confirmed (odds ratio, 3.883; 95% confidence interval, 1.141–13.212; P= 0.030).
Conclusions
We confirmed that the overweight category was a predictor of histological remission after first-line treatment with a biological agent. However, as BMI does not account for skeletal muscle mass, future studies are required to confirm the correlation between skeletal muscle mass and histological remission.

914 View
136 Download

Colorectal neoplasia

A survey of current practices in post-polypectomy surveillance in Korea: Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Eun Ran Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoon Yang, on behalf of the Intestinal Tumor Research Group of the Korean Association for the Study of Intestinal Diseases (KASID); Intest Res 2024;22(2):186-207. Published online April 25, 2024; DOI: https://doi.org/10.5217/ir.2023.00109

Abstract PDF Supplementary Material PubReader ePub: Background/Aims
We investigated the clinical practice patterns of post-polypectomy colonoscopic surveillance among Korean endoscopists.
Methods
In a web-based survey conducted between September and November 2021, participants were asked about their preferred surveillance intervals and the patient age at which surveillance was discontinued. Adherence to the recent guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer (USMSTF) was also analyzed.
Results
In total, 196 endoscopists completed the survey. The most preferred first surveillance intervals were: a 5-year interval after the removal of 1–2 tubular adenomas < 10 mm; a 3-year interval after the removal of 3–10 tubular adenomas < 10 mm, adenomas ≥ 10 mm, tubulovillous or villous adenomas, ≤ 20 hyperplastic polyps < 10 mm, 1–4 sessile serrated lesions (SSLs) < 10 mm, hyperplastic polyps or SSLs ≥ 10 mm, and traditional serrated adenomas; and a 1-year interval after the removal of adenomas with highgrade dysplasia, >10 adenomas, 5–10 SSLs, and SSLs with dysplasia. In piecemeal resections of large polyps ( > 20 mm), surveillance colonoscopy was mostly preferred after 1 year for adenomas and 6 months for SSLs. The mean USMSTF guideline adherence rate was 30.7%. The largest proportion of respondents (40.8%–55.1%) discontinued the surveillance at the patient age of 80–84 years.
Conclusions
A significant discrepancy was observed between the preferred post-polypectomy surveillance intervals and recent international guidelines. Individualized measures are required to increase adherence to the guidelines.

1,637 View
71 Download

IBD

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease: Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim, on behalf of Seoul National University Inflammatory Bowel Disease Research Network (SIRN); Intest Res 2023;21(2):244-251. Published online August 8, 2022; DOI: https://doi.org/10.5217/ir.2022.00057

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This study aims to evaluate the effect of concomitant AS on IBD outcomes.
Methods
Among the 4,722 patients with IBD who were treated in 3 academic hospitals from 2004 to 2021, 55 were also diagnosed with AS (IBD-AS group). Based on patients’ electronic medical records, the outcomes of IBD in IBD-AS group and IBD group without AS (IBD-only group) were appraised.
Results
The proportion of patients treated with biologics or small molecule therapies was significantly higher in IBD-AS group than the proportion in IBD-only group (27.3% vs. 12.7%, P= 0.036). Patients with both ulcerative colitis and AS had a significantly higher risk of biologics or small molecule therapies than patients with only ulcerative colitis (P< 0.001). For univariable logistic regression, biologics or small molecule therapies were associated with concomitant AS (odds ratio, 4.099; 95% confidence interval, 1.863–9.021; P< 0.001) and Crohn’s disease (odds ratio, 3.552; 95% confidence interval, 1.590–7.934; P= 0.002).
Conclusions
Concomitant AS is associated with the high possibility of biologics or small molecule therapies for IBD. IBD patients who also had AS may need more careful examination and active treatment to alleviate the severity of IBD.

Citations

Citations to this article as recorded by

Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
Frontiers in Medicine.2023;[Epub] CrossRef

4,441 View
442 Download
1 Web of Science
1 Crossref

Statement

Cancer

Clinical practice guideline for endoscopic resection of early gastrointestinal cancer: Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong Yeul Lee, Jeong-Sik Byeon, Chan Guk Park, Joo Young Cho, Soo Teik Lee, Hoon Jai Chun; Intest Res 2021;19(2):127-157. Published online October 13, 2020; DOI: https://doi.org/10.5217/ir.2020.00020

Abstract PDF Supplementary Material PubReader ePub

Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.

Citations

Citations to this article as recorded by

A proposal for grading the risk of lymph node metastasis after endoscopic resection of T1 colorectal cancer
Zhenghua Piao, Rong Ge, Chunnian Wang
International Journal of Colorectal Disease.2023;[Epub] CrossRef
A DSC Test for the Early Detection of Neoplastic Gastric Lesions in a Medium-Risk Gastric Cancer Area
Valli De Re, Stefano Realdon, Roberto Vettori, Alice Zaramella, Stefania Maiero, Ombretta Repetto, Vincenzo Canzonieri, Agostino Steffan, Renato Cannizzaro
International Journal of Molecular Sciences.2023; 24(4): 3290. CrossRef
Chasm between Public Perceptions and Epidemiological Data on Colorectal Cancer
Su Bee Park, Min Seob Kwak, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2023; 17(3): 449. CrossRef
Calcium, Vitamin D, and Colorectal Cancer
Young-Jo Wi, Soo-Young Na
The Korean Journal of Gastroenterology.2023; 82(2): 47. CrossRef
Effectiveness and Safety of Endoscopic Submucosal Dissection for Colorectal Neoplasm in Patients with High Charlson Comorbidity Index Score: A HASID Multicenter Study
Dong-Hyun Kim, Yong-Wook Jung, Byung-Chul Jin, Hyung-Hoon Oh, Hyo-Yeop Song, Seong-Jung Kim, Dae-Seong Myung, Sang-Wook Kim, Jun Lee, Geom-Seog Seo, Young-Eun Joo, Hyun-Soo Kim
Journal of Clinical Medicine.2023; 12(19): 6255. CrossRef
Endoscopic management of pseudo-lumen stapling following laparoscopic esophagojejunostomy: A case report
Seung Soo Lee
International Journal of Surgery Case Reports.2023; 111: 108830. CrossRef
Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
Intestinal Research.2023; 21(4): 510. CrossRef
Summary and comparison of recently updated post-polypectomy surveillance guidelines
Yoon Suk Jung
Intestinal Research.2023; 21(4): 443. CrossRef
Advanced Endoscopic Resection Techniques in Cirrhosis—A Systematic Review and Meta-Analysis of Outcomes
Saurabh Chandan, Smit Deliwala, Shahab R. Khan, Daryl Ramai, Babu P. Mohan, Mohammad Bilal, Antonio Facciorusso, Lena L. Kassab, Faisal Kamal, Banreet Dhindsa, Abhilash Perisetti, Douglas G. Adler
Digestive Diseases and Sciences.2022; 67(10): 4813. CrossRef
Prognosis and risk factors of electrocoagulation syndrome after endoscopic submucosal dissection in the colon and rectum. Large cohort study
Seong-Jung Kim, Su Young Kim, Jun Lee
Surgical Endoscopy.2022; 36(8): 6243. CrossRef
Comparison between Endoscopic Submucosal Dissection and Surgery in Patients with Early Gastric Cancer
Meng Qian, Yuan Sheng, Min Wu, Song Wang, Kaiguang Zhang
Cancers.2022; 14(15): 3603. CrossRef
Endoscopic methods for the detection and treatment of gastric cancer
Negar Niknam, Steven Obanor, Linda A. Lee
Current Opinion in Gastroenterology.2022; 38(5): 436. CrossRef
Association Between Family History of Gastric Cancer and the Risk of Gastric Cancer and Adenoma: A Nationwide Population-Based Study
Yoon Suk Jung, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
American Journal of Gastroenterology.2022; 117(8): 1255. CrossRef
Colonic Chicken Skin Mucosa Surrounding Colon Polyps Is an Endoscopic Predictive Marker for Colonic Neoplastic Polyps
Yu Mi Lee, Kyung Ho Song, Hoon Sup Koo, Choong-Sik Lee, Inseok Ko, Sang Hyuk Lee, Kyu Chan Huh
Gut and Liver.2022; 16(5): 754. CrossRef
Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef
Feasibility of same-day discharge following endoscopic submucosal dissection for esophageal or gastric early cancer
Jing Wang, Shi-Jie Li, Yan Yan, Peng Yuan, Wei-Feng Li, Chang-Qi Cao, Wei-Gang Chen, Ke-Neng Chen, Qi Wu
World Journal of Gastroenterology.2022; 28(41): 5957. CrossRef
Endoscopic, clinicopathological, and growth characteristics of minute gastric cancer
Zhu Hui Liu, Shi Yuan Lu, Xiao Bo Li, Hui Min Chen, Hao Yan Chen, Xiao Yu Chen, Jing‐Yuan Fang, Yun Cui
Journal of Digestive Diseases.2022; 23(11): 628. CrossRef
Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer
Darina Kohoutova, Matthew Banks, Jan Bures
Cancers.2021; 13(24): 6242. CrossRef

8,414 View
268 Download
22 Web of Science
18 Crossref

Original Articles

Colorectal neoplasia

Clinical features and outcomes in spontaneous intramural small bowel hematoma: cohort study and literature review: Eun Ae Kang, Seung Jun Han, Jaeyoung Chun, Hyun Jung Lee, Hyunsoo Chung, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyun Chae Jung; Intest Res 2019;17(1):135-143. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00085

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Spontaneous intramural small bowel hematoma (SISBH) is an extremely rare complication of anticoagulant or antiplatelet therapy. We assessed the clinical characteristics and outcomes of patients with SISBH according to the anatomical location of the hematoma.
Methods
From January 2003 to February 2016, medical records for all patients hospitalized for SISBH at 2 tertiary referral hospitals were retrospectively reviewed. The primary outcome was requirement for surgery.
Results
A total of 37 patients were enrolled. The mean age was 74.1 years. Among them, 33 patients (89.2%) were taking anticoagulant and/or antiplatelet agents. Duodenal intramural hematoma was detected in 4 patients (10.8%), jejunal in 16 (43.2%), and ileal in 17 (45.9%). Compared to jejunal and ileal involvement, duodenal intramural hematoma was significantly associated with high Charlson comorbidity index and low levels of white blood cells, hemoglobin, and platelets in the blood. SISBH in the duodenum was related to thrombocytopenia in 3 patients following systemic chemotherapy for malignancy. All patients with SISBH showed clinical improvement with conservative therapy. Mean length of hospital stay was 9.35 days. Independent predictors of a hospital stay of more than 7 days were body weight less than 60 kg (odds ratio [OR], 12.213; 95% confidence interval [CI], 1.755–84.998; P=0.011) and a history of cerebrovascular accidents (OR, 6.667; 95% CI, 1.121–39.650; P=0.037).
Conclusions
Compared to jejunal and ileal involvement, thrombocytopenia may result in spontaneous duodenal intramural hematoma among patients who are treated with systemic chemotherapy for malignancies. Patients with SISBH have excellent clinical outcomes with conservative therapy regardless of the anatomical location of the hematoma.

Citations

Citations to this article as recorded by

A Case of Direct-Acting Oral Anticoagulant-Induced Intramural Colon Hematoma Successfully Treated by Laparoscopic Surgery
Daisuke Tomita, Shigeo Toda, Ryo Miyazaki, Shuichiro Matoba, Hiroya Kuroyanagi
Cureus.2024;[Epub] CrossRef
Spontaneous Intramural Small Bowel Hematoma in an Elderly Man with Multiple Myeloma
Sigrid L. Williamson, Aishwarya Suresh, Adrian Ong
The American Surgeon™.2023; 89(6): 2816. CrossRef
Intramural duodenal hematoma: diagnosis and management of a rare entity
Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
Cirugía Española (English Edition).2023; 101(7): 515. CrossRef
Hematoma intramural duodenal: diagnóstico y manejo de una entidad infrecuente
Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
Cirugía Española.2023; 101(7): 515. CrossRef
Jejunal intramural haematoma in a captive African lion (Panthera leo)
Richelle G. Butcher, Baukje Lenting, Alison S. Clarke, Kelly Buckle, Cristina Gans
Veterinary Record Case Reports.2023;[Epub] CrossRef
Spontaneous Duodenal Hematoma: A Rare Complication of Triple Antithrombotic Therapy Case Report
Mazin N Habhab, Asad J Torabi, Julie M Clary, George E Revtyak
Future Cardiology.2023; 19(2): 71. CrossRef
Intestinal Spontaneous Intramural Hematoma Secondary to Anticoagulation Therapy: A Case Report
Karim El Aidaoui, Wahib Lahlou, Abderrahim Bourial, Nawal Bouknani, Chafik El Kettani
Cureus.2023;[Epub] CrossRef
Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B
Wei-Jung Teng, Ching-Huei Kung, Mei-Mei Cheng, Jia-Ruey Tsai, Chia-Yau Chang
Journal of Clinical Medicine.2023; 12(9): 3093. CrossRef
Endoscopic management of intramural spontaneous duodenal hematoma: A case report
Giorgio Valerii, Vittorio Maria Ormando, Carlo Cellini, Luca Sacco, Carmelo Barbera
World Journal of Gastroenterology.2022; 28(20): 2243. CrossRef
Warfarin-induced spontaneous intramural small bowel hematoma presenting as an acute abdomen: A case report
Ding-Han Chen, Khay-Seng Soh, Ying-Tso Wang, Te-Chun Shen
Medicine.2022; 101(35): e30335. CrossRef
Spontaneous duodenal haematoma in a patient taking rivaroxaban
Rebeca de Barros Lopes, Finn McLennan Battleday, Toby Calvert, Rob Gwynne‐Jones, Rebecca Thomas
ANZ Journal of Surgery.2021;[Epub] CrossRef
SPONTANEOUS INTRAMURAL SMALL-BOWEL HEMATOMA: A CAUSE OF ACUTE ABDOMEN IN ANTICOAGULATED PATIENTS
Sergio Gil Rojas, Luis Miguel Estela Villa, Elsa María Jiménez Vicente
Revista Española de Enfermedades Digestivas.2021;[Epub] CrossRef
Small Bowel Obstruction
Allison A. Aka, Jesse P. Wright, Teresa DeBeche-Adams
Clinics in Colon and Rectal Surgery.2021; 34(04): 219. CrossRef
Double Trouble: Spontaneous Duodenal Hematoma of Pancreatic Origin
Luísa Martins Figueiredo, David Valadas Horta, Jorge A. Reis
GE - Portuguese Journal of Gastroenterology.2019; 26(6): 458. CrossRef

27,653 View
252 Download
17 Web of Science
14 Crossref

IBD

Magnetic resonance enterography predicts the prognosis of Crohn's disease: Ji Hoon Lee, Yong Eun Park, Nieun Seo, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim, Joon Seok Lim, Jae Hee Cheon; Intest Res 2018;16(3):445-457. Published online July 27, 2018; DOI: https://doi.org/10.5217/ir.2018.16.3.445

Abstract PDF PubReader ePub

<b>Background/Aims</b><br/>

Magnetic resonance enterography (MRE) has emerged as an important tool in the diagnosis and follow-up of Crohn's disease (CD). The aim of this study was to evaluate whether MRE findings could predict the prognosis of CD.

Methods

In this retrospective study, a total of 173 patients with clinical remission of CD (n=61) or active CD (n=112) were identified. The outcomes of clinical relapse, admission, surgery, and need for other medications according to the MRE findings were evaluated.

Results

The presence of active inflammation on MRE was observed in 93 (83%) patients with clinically active CD and in 44 (72.1%) patients with clinical remission of CD, without a statistically significant difference (P=0.091). In multivariate analysis, active inflammation on MRE increased the risk for clinical relapse (hazard ratio [HR], 6.985; 95% confidence interval [CI], 1.024–47.649) in patients with clinical remission of CD. In patients with clinically active CD, active inflammation on MRE increased the risk for CD-related hospitalization (HR, 2.970; 95% CI, 1.006–8.772).

Conclusions

The presence of active inflammation on MRE was significantly associated with poor prognosis both in patients with clinical remission of CD and in those with active CD.

Citations

Citations to this article as recorded by

The Spectrum of Magnetic Resonance Enterography Findings and the Role of Diffusion-Weighted Imaging in Patients with Active Crohn’s Disease
Arvin Arian, Ghazal Roostaei, Seyede Sahel Rasoulighasemlouei, Foroogh Alborzi Avanaki, Nasser Ebrahimi Daryani
Middle East Journal of Digestive Diseases.2024; 16(1): 23. CrossRef
Distribution of small bowel involvement and its association with clinical outcomes in patients with Crohn’s disease
Jin Park, Hae Young Kim, Yoon Jin Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
Medicine.2023; 102(40): e35040. CrossRef
Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
Kyunghwan Oh, Eun Hye Oh, Soo Min Noh, Seong Ho Park, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Clinical and Translational Gastroenterology.2022; 13(1): e00442. CrossRef
MR Enterography in Crohnʼs Disease: Comparison of Contrast Imaging with Diffusion-weighted Imaging and a special Form of Color Coding
Maja Jakob, Maik Backes, Christian Schaefer, Joerg Albert, Angela Geissler
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(10): 1119. CrossRef
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease
Eléonore Hallé, Mustapha Azahaf, Nicolas Duveau, Thomas Lambin, Maria Nachury, Julien Branche, Romain Gérard, Clémentine Lauriot Dit Prevost, Pauline Wils, Pierre Desreumaux, Olivier Ernst, Benjamin Pariente
Digestive Diseases and Sciences.2020; 65(9): 2664. CrossRef
Magnetic Resonance Enterography and Capsule Endoscopy in Patients Undergoing Patency Capsule for the Evaluation of Small Bowel Crohn’s Disease: A Korean Clinical Experience
Hyun Seok Lee, Yun Jeong Lim, Jin-Hee Jung, Ji Hyung Nam, Junseok Park, Sun Hyung Kang, Ki Bae Kim, Hoon Jai Chun
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef
Beyond Crohn Disease
Michael S. Furman, Edward Y. Lee
Radiologic Clinics of North America.2020; 58(3): 517. CrossRef
Mucosal healing in Crohn’s disease: new insights
Salvatore Cucchiara, Giulia D’Arcangelo, Sara Isoldi, Marina Aloi, Laura Stronati
Expert Review of Gastroenterology & Hepatology.2020; 14(5): 335. CrossRef
Changes in the Management of Patients with Crohn’s Disease Based on Magnetic Resonance Enterography Patterns
Evelyn Sayuri S. Chinem, Barbara C. Esberard, Andre da L. Moreira, Tatiana G. Barbassa, Guilherme M. da Cunha, Antonio Jose de V. Carneiro, Heitor S. de Souza, Ana Teresa P. Carvalho
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef

7,037 View
104 Download
9 Web of Science
10 Crossref

Focused Review: Intestinal Behçet's Disease

Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease: Hyun Jung Lee, Jae Hee Cheon; Intest Res 2017;15(3):311-317. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.311

Abstract PDF PubReader ePub

Intestinal Behçet's disease (BD), generally accepted as a type of inflammatory bowel disease (IBD), could be diagnosed when patients with BD have objectively documented gastrointestinal symptoms and intestinal ulcerations. Similar to IBD, intestinal BD has an unpredictable disease course with relapse and remission and is often related to a poor prognosis. However, there is no single gold standard for assessment of the disease activity of intestinal BD, and its diagnosis and management depend heavily on expert opinions. The Korean IBD Study Group recently developed novel diagnostic criteria based on colonoscopy findings and clinical manifestations using a modified Delphi process to overcome drawbacks of previously used consensus for the diagnosis of intestinal BD. In addition, the recently developed disease activity index for intestinal BD, consisting of a relatively simple 8-point index, could also help in determining treatment strategies and monitoring therapeutic responses. In this review, the progress in the diagnosis and disease activity measurement of intestinal BD will be discussed.

Citations

Citations to this article as recorded by

Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study
Xiaoman Zu, Shanshan Xiong, Yaming Lu, Ning Zhang, Shu Xu, Rui Feng, Baili Chen, Zhirong Zeng, Minhu Chen, Yao He
Clinical Therapeutics.2024; 46(3): 201. CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef
Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 276. CrossRef
Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study
Jung-Bin Park, So Jung Han, Seung Bum Lee, Dong Hyun Kim, Jae Hee Cheon, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Soo Jung Park, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 265. CrossRef
Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis
Qingfeng Zhang, Chunyan Ma, Rongrong Dong, Weizhen Xiang, Meiqi Li, Zhenzhen Ma, Qingrui Yang
Yonsei Medical Journal.2022; 63(2): 148. CrossRef
Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet’s disease: Case report and the review of literature
Takashi Onaka, Kazuhisa Nakano, Yuri Uemoto, Naoto Miyakawa, Yasuyuki Otsuka, Aiko Ogura-Kato, Fumie Iwai, Yoshiya Tanaka, Akihito Yonezawa
Modern Rheumatology Case Reports.2022; 6(2): 273. CrossRef
¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet’s Disease
Burak İnce, Ali Kibar, Sertaç Asa, Rabia Lebriz Uslu Beşli, Muhammet Sait Sağer, Ahmet Emre Eşkazan, Ali İbrahim Hatemi, Gülen Hatemi, Kerim Sönmezoğlu
Molecular Imaging and Radionuclide Therapy.2022; 31(1): 57. CrossRef
Clinical Course of Patients with Intestinal Behçet’s Disease According to Consensus-Based Diagnostic Categories
Yu Young Joo, Bo-In Lee, Seung-Jun Kim, Han Hee Lee, Jin Su Kim, Jae Myung Park, Young-Seok Cho, Kang Moon Lee, Sang Woo Kim, Hwang Choi, Myung-Gyu Choi
Gut and Liver.2022; 16(5): 746. CrossRef
Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet’s Disease with Intestinal Involvement and Crohn’s Disease
Fatma Alibaz-Oner, Rabia Ergelen, Ilkay Ergenc, Gizem Seven, Ayten Yazıcı, Ayse Cefle, Cemal Bes, Ozlen Atug, Haner Direskeneli
Digestive Diseases and Sciences.2021; 66(8): 2750. CrossRef
Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2021; 36(8): 2141. CrossRef
Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
Jihye Park, Daeun Jeong, Youn Wook Chung, Seunghan Han, Da Hye Kim, Jongwook Yu, Jae Hee Cheon, Ji-Hwan Ryu
Scientific Reports.2021;[Epub] CrossRef
Behçet syndrome
Yusuf Yazici, Gulen Hatemi, Bahram Bodaghi, Jae Hee Cheon, Noburu Suzuki, Nicola Ambrose, Hasan Yazici
Nature Reviews Disease Primers.2021;[Epub] CrossRef
C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet’s disease
Eun Ae Kang, Jung Won Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Min Soo Cho, Jae Hee Cheon
BMC Gastroenterology.2021;[Epub] CrossRef
Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents
Yehyun Park, Jae Hee Cheon
Current Gastroenterology Reports.2020;[Epub] CrossRef
A20 Haploinsufficiency in a Chinese Patient With Intestinal Behcet's Disease-Like Symptoms: A Case Report
Yu Chen, Huanjun Huang, Yao He, Minhu Chen, Ursula Seidler, De'an Tian, Fang Xiao
Frontiers in Immunology.2020;[Epub] CrossRef
Association of Clinical Phenotypes in Haploinsufficiency A20 (HA20) With Disrupted Domains of A20
Yu Chen, Zhenghao Ye, Liping Chen, Tingting Qin, Ursula Seidler, De'an Tian, Fang Xiao
Frontiers in Immunology.2020;[Epub] CrossRef
Behсet's disease: intestinal damage
R. G. Goloeva, Z. S. Alekberova
Rheumatology Science and Practice.2019; 56(6): 767. CrossRef
Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab
Zhe Yan, Bei-Bei Cui, Yong-Yang Yu, Geng Yin, Xiao-Min Cen, Qi-Bing Xie
Medicine.2019; 98(9): e14624. CrossRef
Intestinal manifestations of Behçet's disease
R G Goloeva, Z S Alekberova, T A Lisitsyna, E A Stepanova, L P Orlova
Terapevticheskii arkhiv.2019; 91(5): 111. CrossRef
Cancer Risk in Patients with Intestinal Behçet’s Disease: A Nationwide Population-Based Study
Minkyung Han, Yoon Suk Jung, Won Ho Kim, Jae Hee Cheon, Sohee Park
Gut and Liver.2018; 12(4): 433. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef

8,938 View
185 Download
20 Web of Science
21 Crossref

Case Reports

Colitis Cystica Profunda Masquerading as a Pneumatosis Cystoides Intestinalis: A Case Report: Eun Suk Jung, Jae Hee Cheon, Kyong Joo Lee, Hyun Jung Lee, Hui Won Jang, Young Eun Chon, Kyu Sik Jung, Seonjung Chang, Sung Pil Hong, Tae Il Kim, Won Ho Kim; Intest Res 2010;8(2):187-190. Published online December 30, 2010; DOI: https://doi.org/10.5217/ir.2010.8.2.187

Abstract PDF: Colitis Cystica Profunda (CCP) is an uncommon and benign disease entity characterized by mucoid cysts located in the submucosal layer of the colon. It can mimic cystic submucosal tumors or mucinous adenocarcinoma and is usually located in the rectum. CCP is found in the ascending colon less frequently. CCP manifesting as multiple cystic tumors, similar to pneumatosis cystoides intestinalis, has not yet been reported. Recently, a case of CCP mimicking pneumatosis cystoides intestinalis in the ascending colon was treated. Here this case is reported and the literature reviewed. (Intest Res 2010;8:187-190)

2,362 View
28 Download

Clinical Experience of Thalidomide in the Treatment of Korean Patients with Intestinal BehcӇet's Disease: Pilot Experience in a Single Center: Hyun Jung Lee, Jae Hee Cheon, Kyong Joo Lee, Hui Won Jang, Kyu Sik Jung, Eun Suk Jung, Jin Ha Lee, Seung Min Jeon, Sung Pil Hong, Tae Il Kim, Won Ho Kim; Intest Res 2010;8(1):63-69. Published online June 30, 2010; DOI: https://doi.org/10.5217/ir.2010.8.1.63

Abstract PDF

Intestinal BehcӇet's disease (BD) often leads to severe complications, such as perforation or massive bleeding, and therefore is one of the major causes of morbidity and mortality. As thalidomide has been identified and its anti-inflammatory and immunomodulatory properties clarified, this drug has been used in cases of systemic BD with some success. Herein we report a case series of four patients with intestinal BD to share our clinical experience with thalidomide treatment. We studied the effects of thalidomide in four patients who had a chronic relapse of intestinal BD requiring the frequent use of systemic steroids due to refractoriness to prior treatments, such as 5-aminosalycylic acid and immunosuppressants. Pre- and post-treatment clinical and laboratory data, including clinical symptoms, laboratory data, disease activity index for intestinal BD, and thalidomide toxicity were recorded. Three of the four patients had a clinical and radiologic improvement after thalidomide treatment and all of the patients discontinued steroid therapy. Although two patients tolerated thalidomide, two patients could not continue the treatment because they suffered from edema and neutropenia. Thalidomide could be considered a therapeutic option for the treatment of intestinal BD. (Intest Res 2010;8:63-69)

Citations

Citations to this article as recorded by

Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef
An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
Kader Cetin Gedik, Micol Romano, Roberta A. Berard, Erkan Demirkaya
Current Treatment Options in Rheumatology.2020; 6(2): 99. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
Update on the Medical Management of Gastrointestinal Behçet’s Disease
Giuseppe Lopalco, Donato Rigante, Vincenzo Venerito, Claudia Fabiani, Rossella Franceschini, Michele Barone, Giovanni Lapadula, Mauro Galeazzi, Bruno Frediani, Florenzo Iannone, Luca Cantarini
Mediators of Inflammation.2017; 2017: 1. CrossRef
An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease
Jae Hee Cheon, Won Ho Kim
Current Opinion in Rheumatology.2015; 27(1): 24. CrossRef
Update on the Treatment of Intestinal Behçet's Disease
Kyung-Jo Kim
Journal of Rheumatic Diseases.2014; 21(4): 176. CrossRef
The Medical Treatments of Intestinal Behçet's Disease: An Update
Hye Won Lee, Won Ho Kim, Jae Hee Cheon
Intestinal Research.2013; 11(3): 155. CrossRef
Efficacy of Infliximab in Intestinal Behçet’s Disease
Jin Ha Lee, Jae Hee Cheon, Seong Woo Jeon, Byong Duk Ye, Suk-Kyun Yang, Young-Ho Kim, Kang-Moon Lee, Jong Pil Im, Joo Sung Kim, Chang Kyun Lee, Hyo Jong Kim, Eun Young Kim, Kyeong Ok Kim, Byung Ik Jang, Won Ho Kim
Inflammatory Bowel Diseases.2013; : 1. CrossRef

2,635 View
28 Download
8 Crossref

First
Prev
Page of 1
Next
Last

Search